Tris acquires Pfizer's NextWave ADHD-focused subsidiary
Tris Pharma Inc. acquired Pfizer Inc.'s attention deficit hyperactivity disorder (ADHD)-focused subsidiary NextWave Pharmaceuticals Inc.
- Specialty Pharmaceuticals
- Controlled Release
- Acquisition of Private Biotech
- Full Acquisition
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.